Yawan mutanen da ke fama da rigakafi "na iya" suna buƙatar haɓakar rigakafin COVID-19

Curtis J. Webinar mara lafiya: rigakafin COVID-19 da magani. Mai Magana: Gidauniyar Bincike ta Rheumatism. Mayu 11, 2021 (Q&A na Farko).
Curtis J. Webinar mara lafiya: rigakafin COVID-19 da magani. Mai Magana: Gidauniyar Bincike ta Rheumatism. Mayu 11, 2021 (Q&A na Farko).
Jeffrey R. Curtis, MD, shugabar ƙungiyar COVID-19 Vaccine Clinical Guidance Working Group of the American Academy of Rheumatology, ya ce marasa lafiya da suka kamu da cutar za su “yiwu” suna buƙatar yin amfani da magungunan COVID-19 akai-akai a nan gaba.
Curtis, masanin ilimin rheumatologist, likitan dabbobi, kuma farfesa a fannin likitanci a Jami'ar Alabama a Birmingham, ya fadawa mahalarta taron Q&A na baya-bayan nan da Gidauniyar Bincike ta Rheumatology ta gudanar cewa ya yi imanin cewa rigakafin COVID-19 na iya zama gama gari a cikin wadannan marasa lafiya.
"Hakika, akwai kimiyya da yawa, kuma kimiyya kullum tana ci gaba. Duk abin da kuke tunanin kun san wannan watan, wata mai zuwa na iya bambanta, don haka saboda wannan dalili, ina tsammanin duk abin da muke faɗi ko magana game da daren yau yana iya canzawa, ”Curtis ya gaya wa masu halarta a dandalin tattaunawa. "Ni da kaina ina tsammanin mutane na iya buƙatar masu haɓakawa. Wataƙila ba haka lamarin yake ga kowa ba, amma ina tsammanin yana iya zama gama gari don samun abin ƙarfafawa sannan a yi shi lokaci-lokaci. Yana iya ƙare sama ko žasa kamar maganin mura, idan ba kowace shekara ba, sannan kuna buƙatar ta aƙalla kowace shekara. "
Ya kara da cewa ya danganta da irin jinyar da majiyyaci ke samu, daidaikun mutane kuma za su iya samun damar cin gajiyar allurar rigakafi ko ma yawan allurar rigakafi.
"Wani a cikin tattaunawar ya tayar da halin da ake ciki cewa mai yiwuwa ba zai zama kashi ko maganin da suke so ba, don haka ya danganta da maganin da kuke samu, wannan wani abu ne da za ku tattauna da mai ba da lafiyar ku," in ji Curtis. "Amma ina tsammanin cewa manufar ƙarfafawa na iya zama kyakkyawa."
Lokacin da aka tambaye shi game da yiwuwar amfani da tsarin rigakafin Pfizer ko Moderna tare da haɓaka wani kamfani, Curtis ya amsa cewa yana fatan masana za su ba da shawarar cewa mutane su ci gaba da amfani da wannan maganin a matsayin rigakafin farko.
Ya ce: "Da alama wannan ba zai zama cikakken nazari a nan gaba ba." "Ina cike da tsammanin. Ya kamata ku tsaya kan goyon bayan da kuka samu tun farko."
Curtis ya kuma yi sharhi game da wasu magungunan rheumatic, gami da rituximab (Rituxan, Genentech) da mycophenolate mofetil, wanda zai iya rage tasirin rigakafin COVID-19.
Ya ce: "Ina tsammanin Rituximab zai kasance daya daga cikin magunguna masu ban sha'awa." Rituximab yana da tasiri sosai wajen kawar da ƙwayoyin B da kuma sa jiki ya yi wahala don samar da ƙwayoyin rigakafi. Wannan abu ne mai kyau lokacin da kake jinyar wani abu tare da ƙwayoyin rigakafi wanda kake son kawar da shi, amma idan kana son taimakawa tsarin rigakafi don yaki da cututtuka a nan gaba, bazai zama abu mai kyau ba. ”
Rituximab na iya rage amsawar rigakafi zuwa mafi girma fiye da sauran jiyya. Mycophenolate mofetil shine wani. "Waɗannan abubuwa ne guda biyu da zan iya yin shakkar, don in gamsu da cewa wani yana da cikakkiyar kariya daga COVID-19."
A cewar Curtis, batutuwa ciki har da masu hana JAK da rage halayen rigakafi, gami da ACR COVID-19 Vaccine Clinical Guidance Working Group suma sun ja hankali.
Curtis ya ce: "Wannan shine dalilin da ya sa wasu daga cikinsu ke ba da shawarar cewa, idan zai yiwu, ɗan gajeren lokaci na jiyya na iya zama hikima." “Wannan ba gargadi ba ne na gaba ɗaya, yakamata ku yi hakan a kowane farashi, amma tare da rheumatism ku Yi magana da likitan mara lafiya. ACR ta sami sabbin shawarwari daga rukunin aiki na jagora, kuma an ba da waɗannan shawarwarin a cikin ƴan kwanakin da suka gabata. "
Wani sabon binciken da aka buga a cikin Gut ya gano cewa marasa lafiya da ke da cututtukan hanji masu kumburi waɗanda suka karɓi infliximab sun sami raguwar amsawar rigakafi ga rigakafin COVID-19 nan da nan bayan allurar farko (Remicade, Janssen). Koyaya, lokacin da mai haƙuri ɗaya daga baya ya sami kashi na biyu na jiyya, amsawar rigakafi ta zama kamar al'ada.
A cewar Curtis, wannan ya tsawaita lokacin karɓar kashi na biyu don adana allurai a wasu ƙasashe, ba kawai ga IBD da infliximab ba, har ma ga marasa lafiya da yawancin cututtuka na autoimmune da jiyya.
"Idan kana zaune a wata ƙasa kuma Amurka ba ɗaya daga cikinsu ba, to wannan shine don tsawaita lokacin daga kashi na farko zuwa kashi na biyu don adana adadin ta yadda kowa zai iya samun kashi na farko. Ina tsammanin, Wannan bazai zama kyakkyawan ra'ayi ba ga mutanen da ke fuskantar maganin rigakafi don cutar Crohn ko lupus, vasculitis, arthritis na rheumatoid ko wasu cututtuka." Curtis. "A gaskiya, ba kawai infliximab ba ne, har ma da Remicade da [biosimilars] Inflectra da Renflexis. Ina kuma zargin cewa yawancin magungunan mu iri daya ne.
Ya kara da cewa a yanzu akwai bincike da yawa kan martanin marasa lafiya da ke da cututtukan autoimmune ga rigakafin COVID-19 bayan allurai na farko da na biyu. Sakamakon ya nuna cewa za a samar da cikakkun ƙwayoyin rigakafi ne kawai bayan an kammala cikakken jerin alluran rigakafi. amsa.
Curtis ya ce: "Yanzu, akwai wasu nazarce-nazarce a cikin wallafe-wallafe, suna nazarin abin da ke faruwa bayan shan kashi na farko." Amsar rigakafin mutane da yawa yana da kyau, amma ga mutane da yawa, tasirin ba shi da kyau sosai. Don haka, ina tsammanin cewa babban bayanan da na koya daga wasu rubuce-rubucen da na yi bitar suna cikin jama'a, wasu kuma an aiko mini da su a asirce, kuma da gaske ya kamata ku karɓi kashi na biyu.
"Wannan gaskiya ne musamman idan kuna da cutar ta autoimmune ko kuma kuna karɓar magungunan da ke shafar rigakafi, saboda idan kun kammala duk jerin karatun kamar yadda ake tsammani, wasu mutane za su ci gaba da kasancewa cikin haɗari kuma kafin a sami martanin rigakafin da ake tsammanin, sun samu. kashi na biyu.” Ya kara da cewa. "Sa'an nan, gabaɗaya magana, marasa lafiya da rheumatism suna da alama suna da kariya sosai bayan sun karɓi kashi na biyu, amma akwai wasu keɓancewa."

https://www.youtube.com/watch?v=-JaasdO90oM

https://www.youtube.com/watch?v=wAS7TSJrNVg